- Turkey - North America
- Poultry & Meats - Central America
- Poultry - Europe
- Poultry - Asia
- How We Approach Animal Welfare
- Leadership & Accountability
- Scope of Cargill's Commitment
- Animal Welfare Objectives
- Measurement & Reporting
- Supply Chain Compliance
- Supporting Global Excellence
- Sharing Knowledge
- Ethical Treatment
- Role of Technology
- Recognition of Our Efforts
- Customer Webinar
- Role of Alternative Proteins
The Role of Technology
At this time, and until further notice, Cargill will not accept animals at its harvest facilities that are a direct result of the somatic cell nuclear transfer cloning process.
Cargill U.S. beef and poultry businesses, support the United States Food and Drug Administration (FDA) Guidance For Industry 213, which states that the use of growth promoting antibiotics are not in line with the proposed judicious use of antimicrobial drugs. Similarly, the Cargill Canadian poultry business supports the Responsible Antimicrobial Use in the Canadian Chicken and Turkey Sectors policy which proposes withdrawing the preventive use of Category 1 antibiotics.
Cargill’s Honeysuckle White and Shady Brook Farms turkeys are raised without the use of growth promoting antibiotics. Similarly, the Cargill Canadian poultry business supports the Responsible Antimicrobial Use in the Canadian Chicken and Turkey Sectors policy which proposes withdrawing the preventive use of antibiotics important to human health. Cargill Europe abides by the European Union’s ban on the use of growth promoting substances.
At Cargill, we are committed to reducing the use of human antibiotics in food production. We invest in research and innovation focused on reducing the need to use antibiotics while maintaining our commitment to animal welfare and the production of safe, nutritious, affordable food. While supporting reduction in antibiotic use, we also believe the judicious therapeutic use of animal antibiotics helps maintain the safety of world food supplies. Judicious use prevents sick animals from entering the food supply and ensures animals do not unnecessarily suffer from disease.
We promote transparency in antibiotic use and work with stakeholders to develop metrics to measure use. We will share our progress toward fulfilling our antibiotic reduction commitments with the public.
In summer 2014, Cargill announced it would eliminate antibiotics used for growth promotion in its US turkey business, which was achieved by the 2015 holiday season.
In early 2016, Cargill announced a 20 percent reduction in the use of shared-class antibiotics for beef cattle in its US feed yards, as well as for those cattle in feed yards of a strategic partner that supplies cattle to Cargill. The total annual number of cattle represented by this decision is more than one million. Cargill was the first major cattle feeder to do this.
In summer 2016, Cargill ended the use of gentamicin – an antibiotic used in both human and animal healthcare – for disease prevention in turkeys harvested for its two largest brands, Honeysuckle White® and Shady Brook Farms®. Turkeys will continue to receive antibiotics for control and treatment of disease. Cargill’s turkey products covered by this decision will be available in the marketplace by Jan. 1, 2017. Correspondingly, Cargill is expanding its antibiotic-free turkey products through the creation of its new Honest Turkey™ product line. These products will be differentiated from conventional turkey offerings because they come from turkeys that are never treated with antibiotics.
These are a few examples of our efforts to reduce antibiotic use in food animals.